Critical Analysis: Intra-Cellular Therapies, Inc. v. Controller of Patents (2026:DHC:5394) C.A.(COMM.IPD-PAT) 24/2023 | Delhi High Court | Decided: 06.07.2026 I. Doctrinal Analysis: Novelty and the "Coverage vs. Disclosure" Question A. The genus-species anticipation problem The core novelty dispute was a classic Markush-genus-versus-species-selection issue. The appellant argued that arriving at the claimed species from the generic Formula I of D1/D7 required " multiple selections " among independent variables (R1–R6), and that the Controller impermissibly relied on more than one prior art document to construct a single "closest prior art" novelty attack — a submission with real doctrinal pedigree, since novelty (unlike obviousness) is ordinarily tested against a single prior document read as a whole. The Court's response — invoking AstraZeneca AB and Boehringer Ingelheim v. Vee Excel — collapses the " covered vs. disclosed " dist...
Summary The Delhi High Court clarified that trademark protection extends only to the specific goods within the class for which the mark is registered, and a proprietor cannot claim exclusivity over all goods in that class merely because of a similar mark, particularly when not using the mark for those goods. Introduction This appeal challenges the judgment of the Patiala House District Court, which dismissed the Appellant's application for interim injunction under Order 39 Rules 1 and 2 of the Code of Civil Procedure, 1908. The underlying suit seeks permanent injunction restraining the Respondent from using the trademark "PRUEASE" (Impugned Mark) on the ground that it is deceptively similar to the Appellant's trademark "PRO-EASE" (Subject Mark). Both marks are registered in Class 5 of the Trade Marks Registry, but are used for entirely different product categories within that class. Background and Facts The Appellant conceived and adopted the Subject Mark ...